Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Expectations By $0.06 EPS

Allogene Therapeutics (NASDAQ:ALLO) released its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Trading Down 8.3 %

NASDAQ ALLO traded down $0.17 on Thursday, hitting $1.89. 1,980,427 shares of the stock traded hands, compared to its average volume of 3,078,132. The stock has a 50-day moving average of $1.95 and a 200 day moving average of $2.33. Allogene Therapeutics has a twelve month low of $1.32 and a twelve month high of $5.11. The company has a market capitalization of $396.28 million, a P/E ratio of -1.21 and a beta of 1.02.

Insider Transactions at Allogene Therapeutics

In related news, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now directly owns 250,713 shares in the company, valued at $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,710 shares of company stock worth $92,125. 24.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALLO. Piper Sandler dropped their target price on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.95.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).